0.782

1.23% 0.0095

Pre-market: .80 0.018 +2.30%

Tenaya Therapeutics Inc (TNYA)

Overview News Price History Option Chain Financials Discussions Forecast

Tenaya Therapeutics Inc stock is traded at $0.782, with a volume of 2.61M. It is up +1.23% in the last 24 hours and up +16.33% over the past month. Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Previous Close:

$0.7725

Open:

$0.77

24h Volume:

2.61M

Relative Volume:

0.58

Market Cap:

$169.69M

Revenue:

Net Income/Loss:

$-90.60M

P/E Ratio:

-1.2476

EPS:

-0.6268

Net Cash Flow:

$-68.88M

1W Performance:

-0.70%

1M Performance:

+16.33%

6M Performance:

-42.50%

1Y Performance:

+81.69%

1-Day Range:

$0.76

$0.8173

1-Week Range:

$0.76

$0.8242

52-Week Range:

$0.4253

$2.35

Tenaya Therapeutics Inc Stock (TNYA) Company Profile

Name

Tenaya Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

415-865-2066

Address

171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

TNYA's Discussions on Twitter

Compare TNYA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNYA Tenaya Therapeutics Inc	0.782	167.63M	0	-90.60M	-68.88M	-0.6268
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-10-24	Initiated	William Blair	Outperform
Nov-30-23	Initiated	Leerink Partners	Outperform
Jun-15-22	Initiated	H.C. Wainwright	Buy

Tenaya Therapeutics Inc Stock (TNYA) Latest News

May 23, 2026

What do we know so far from TN-201 trial? - Moomoo

May 23, 2026

TN-201 and TN-401 - Moomoo

May 23, 2026

May 22, 2026

TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill

May 22, 2026

May 21, 2026

Tenaya Therapeutics' gene therapy data highlights early heart rhythm improvements - MSN

May 21, 2026

May 20, 2026

Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock By Investing.com - Investing.com Australia

May 20, 2026

May 19, 2026

Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares - Investing.com UK

May 19, 2026

Tenaya Therapeutics CMO Tingley Whittemore sells $2,476 in stock - Investing.com UK

May 19, 2026

Tenaya Therapeutics CEO Ali Faraz sells $2,689 in shares By Investing.com - Investing.com South Africa

May 19, 2026

Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale - Investing.com UK

May 19, 2026

Tenaya Therapeutics SVP Tomohiro Higa reports $1,177 stock sale By Investing.com - Investing.com Canada

May 19, 2026

Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding - Stock Titan

May 19, 2026

Tenaya Therapeutics (TNYA) CMO sells 3,121 shares for tax withholding - Stock Titan

May 19, 2026

Tenaya Therapeutics (TNYA) SVP sells 1,485 shares to cover RSU taxes - Stock Titan

May 19, 2026

Canaccord Genuity Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA) - The Globe and Mail

May 19, 2026